Armstrong, April W.
Hong, H. Chih-Ho
Calimlim, Brian M.
Buessing, Marric G.
Crowell, Marjorie M.
Silverberg, Jonathan I.
Funding for this research was provided by:
AbbVie
Article History
Received: 31 May 2024
Accepted: 12 July 2024
First Online: 30 July 2024
Declarations
:
: April Armstrong has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer, and Ventyx. H. Chih-Ho Hong has served as an investigator, speaker, advisor and/or consultant for Abbvie, Amgen, Arcutis, Bausch Health, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Evelo Biosciences, Galderma, GSK, Incyte, Janssen, Leo Pharma, Medimmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Roche, and UCB. Brian Calimlim is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options and patents. Marric Buessing and Marjorie Crowell are employees of Medicus Economics LLC, which was paid fees by AbbVie to conduct the research in the manuscript. Jonathan Silverberg reports personal fees from Abbvie, Afyx, Arena, Asana, BioMX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, and Sanofi-Genzyme; institution received grants from Galderma.
: This study did not require institutional review board approval as it did not access identifiable patient information or have direct interaction with patients. This post hoc analysis used data from previously conducted studies and did not contain data from any new studies with human participants or animals performed by any of the authors.